Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patients.

Catalano M, Venturi G, Salfi A, Bloise F, Paolieri F, Galli L, Sisani M, Doni L, Roviello G.

DOI: 10.1080/1750743x.2025.2482510
Published: 2025-03-28
Container: Immunotherapy
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/1750743x.2025.2482510,
  title = {Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patients.},
  author = {Catalano M and  Venturi G and  Salfi A and  Bloise F and  Paolieri F and  Galli L and  Sisani M and  Doni L and  Roviello G.},
  year = {2025},
  journal = {Immunotherapy},
  doi = {10.1080/1750743x.2025.2482510},
  url = {https://doi.org/10.1080/1750743x.2025.2482510}
}

RIS

TY  - JOUR
TI  - Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patients.
AU  - Catalano M
AU  -  Venturi G
AU  -  Salfi A
AU  -  Bloise F
AU  -  Paolieri F
AU  -  Galli L
AU  -  Sisani M
AU  -  Doni L
AU  -  Roviello G.
PY  - 2025
JO  - Immunotherapy
DO  - 10.1080/1750743x.2025.2482510
UR  - https://doi.org/10.1080/1750743x.2025.2482510
ER  -

APA

M, C., G, V., A, S., F, B., F, P., L, G., M, S., L, D., & G., R. (2025). Incidence and impact of immune combination therapies adverse events in advanced renal cell carcinoma patients.. Immunotherapy. https://doi.org/10.1080/1750743x.2025.2482510

Source records

europe-pmc · retrieved 2026-09-27T05:07:20.877Z